Novartis has been making waves in the investment sector with numerous key developments provided in the market updates. The pharmaceutical giant, known for its strong value and momentum, has been identified by investors for its consistent dividend payout. It recently topped the market on Tuesday due to robust sales of its blockbuster drugs, resulting in the escalation of its share price and guidance. An agreement was signed with
MorphoSys to execute a delisting and a merger squeeze-out of minority shareholders.
GAMMA Investing LLC decided to sell 155 shares of Novartis, while
HighPoint Advisor Group LLC and
Leo Wealth LLC chose to invest heavily in it. The firm's shares rose after trial data gave promising signs for a new cancer drug filing. However, disappointments like underwhelming Prostate Cancer Drug sales, earnings miss hopes, and lower than expected valuations also exist. In a huge investment move, Novartis agreed to buy
MorphoSys for €2.7/ $2.9 billion getting hold of their cancer drugs and adding a late-stage oncology drug. Novartis also has reportedly been in advanced talks to buy
Cytokinetics. A milestone for Novartis was FDA approval for their Lutathera for pediatric patients.
Novartis Stocks News Analytics from Fri, 18 Aug 2023 07:00:00 GMT to Fri, 21 Jun 2024 18:31:52 GMT -
Rating 7
- Innovation 9
- Information 8
- Rumor -6
